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Abstract
Undoubtedly ovarian cancer is a vexing, incurable disease for patients with recurrent cancer and therapeutic options are
limited. Although the polycomb group gene, Bmi-1 that regulates the self-renewal of normal stem and progenitor cells has
been implicated in the pathogenesis of many human malignancies, yet a role for Bmi-1 in influencing chemotherapy
response has not been addressed before. Here we demonstrate that silencing Bmi-1 reduces intracellular GSH levels and
thereby sensitizes chemoresistant ovarian cancer cells to chemotherapeutics such as cisplatin. By exacerbating ROS
production in response to cisplatin, Bmi-1 silencing activates the DNA damage response pathway, caspases and cleaves
PARP resulting in the induction apoptosis in ovarian cancer cells. In an in vivo orthotopic mouse model of chemoresistant
ovarian cancer, knockdown of Bmi-1 by nanoliposomal delivery significantly inhibits tumor growth. While cisplatin
monotherapy was inactive, combination of Bmi-1 silencing along with cisplatin almost completely abrogated ovarian tumor
growth. Collectively these findings establish Bmi-1 as an important new target for therapy in chemoresistant ovarian cancer.
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Introduction
Ovarian cancer has the highest mortality rate among all
gynecologic malignancies [1]. Despite initial response to surgical
debulking and front-line platinum/taxane chemotherapy, most
tumors eventually develop a drug resistant relapse [2,3]. Evidence
suggests that cisplatin resistance might be the result of a defective
apoptotic program. In this case, increased levels of DNA damage
would be required to induce the signal initiating apoptosis [4,5].
Bmi-1, a polycomb group gene, regulates the proliferative
activity of normal stem and progenitor cells [6]. It is also
indispensable for the self-renewal of neural [7,8] and haemato-
poietic stem cells [9]. Bmi-1 is frequently upregulated in a variety
of cancers including ovarian cancer and its correlation with clinical
grade/stage, lymph node metastasis and poor prognosis has been
reported [10,11,12,13,14,15,16,17,18,19]. Bmi-1 causes neoplastic
transformation of lymphocytes and co-operates with H-Ras giving
rise to metastatic breast cancer in mice [20,21,22], all strongly
suggesting an oncogenic role in epithelial malignancies. In
addition, isolated ovarian cancer stem cells exhibit much higher
Bmi-1 levels compared to the differentiated or parental bulk tumor
cells and have increased resistance to cisplatin and paclitaxel when
compared to the tumor cells [23]. Also the increased expression of
Bmi-1 was one of the key regulatory factors determining a cellular
phenotype captured by the expression of a death-from-cancer
signature in a broad spectrum of therapy-resistant clinically lethal
malignancies [24]. Despite this wealth of information a possible
role for Bmi-1 in influencing chemotherapy response has not been
addressed before. In this context, determining the mechanism by
which Bmi-1 silencing sensitizes the cancer cells to cisplatin would
be important for development of new therapeutic strategies to
combat ovarian cancer.
The most active chemotherapy agents in ovarian cancer are the
platinum analogues, cisplatin and carboplatin. The antitumor
activity of cisplatin (cis-diamminedichloroplatinum (II) was
discovered by Rosenberg and colleagues in 1961 [25]. Cisplatin
has been the most active drug for the treatment of ovarian cancer
for the last 4 decades and the prognosis for women with ovarian
cancer can be defined by the tumor response to cisplatin [26].
Although the majority of patients with ovarian cancer respond to
front-line platinum combination chemotherapy the majority will
develop disease that becomes resistant to cisplatin and will
ultimately succumb to the disease [26]. Thus methods of
preventing or overcoming resistance to cisplatin could have a
major impact in the fight against this disease.
Here we demonstrate that Bmi-1 plays an important role in
sensitization of chemoresistant ovarian cancer cells to cisplatin. We
also show that this sensitization is through a novel pathway
modulated by Bmi-1, namely reactive oxygen species (ROS)
induction causing engagement of the DNA damage response
(DDR) pathway leading to apoptosis. We also establish Bmi-1 as a
valid therapeutic target in vivo using a readily translatable approach
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  21of nanoliposomal delivery of siRNA into an orthotopic mouse
model of ovarian cancer.
Results
Knockdown of Bmi-1 enhances cisplatin sensitivity in
vitro
We have previously shown that reduction of Bmi-1 protein
levels in ovarian cancer cells using microRNA 15a/16 decreases
clonal growth and proliferation [27]. Here, we wanted to test if
knockdown of Bmi-1 affected cisplatin mediated apoptosis in
ovarian cancer cells. Efficient knockdown of Bmi-1 in A-2780 and
CP-70 cells was confirmed by comparing with the scrambled
control transfected cells after 48 h (Fig. 1). The siRNA transfected
cells were treated with cisplatin for 48 h and apoptosis determined
by the Annexin/FITC method. Apoptosis in the chemosensitive
A-2780 control siRNA transfected cells was ,35 and 55% when
treated with 5 or 10 uM cisplatin alone respectively. In contrast,
apoptosis in the chemoresistant CP-70 was ,17 and 40% when
treated with 10 or 20 uM cisplatin alone respectively indicating
resistance of these cells towards cisplatin induced apoptosis (Fig. 1).
Importantly treating the Bmi-1 silenced cells with cisplatin
consistently enhanced apoptosis in both the cell lines by ,15–
20% (Fig. 1). For both the cell lines, the basal level of apoptosis
determined without any treatment was ,10%. Apoptosis
experiments with three additional cell lines such as OVCAR-5,
OV-202 and OV-167 yielded similar results (data not shown).
These data confirmed that knockdown of Bmi-1 could sensitize
ovarian cancer cells to cisplatin induced cell death.
Recently, it has been reported that neurons, thymocytes and
bone marrow cells isolated from Bmi-1 null mice have increased
ROS levels than their wild-type counterparts [28,29]. Further-
more, studies have reported the involvement of ROS generation in
cisplatin-mediated apoptosis [30,31]. Hence, to determine how
silencing of Bmi-1 sensitizes drug-resistant ovarian cancer cells to
cisplatin induced apoptosis, we investigated the possible involve-
ment of ROS. Therefore, Bmi-1 or scrambled-control siRNA
transfected ovarian cancer cells were pre-treated with N-Acetyl
Cysteine (NAC) at 1 mg/ml for 1 h followed by cisplatin
treatment for 48 h. Significant inhibition of cisplatin mediated
apoptosis in both control and Bmi-1 knockdown cells was observed
in the presence of ROS scavenger NAC (Fig. 1). These data
indicate that the augmented apoptosis observed in the cisplatin
treated Bmi-1 silenced cells was due to the involvement of ROS
and led us to determine ROS production as a next logical step.
Knockdown of Bmi-1 increases cisplatin-mediated ROS
production
We next determined ROS production in scrambled control or
Bmi-1 siRNA transfected cells treated with or without cisplatin by
measuring fluorescence using DCFDA. Cisplatin treatment alone
significantly increased ROS generation at 10 uM in A-2780 cells
and at 10 and 20 uM in CP-70 cells. In both the cell lines,
knockdown of Bmi-1 followed by any cisplatin treatment
Figure 1. Bmi-1 knockdown sensitizes ovarian cancer cells to cisplatin through ROS pathway. The top panel demonstrates efficient
knockdown of Bmi-1 by siRNA in the ovarian cancer cell lines (SC=scrambled control siRNA) as determined by Western blot. The bottom panel
demonstrates percent apoptosis as determined by Annexin/FITC-PI staining. Ovarian cancer cells transfected with scrambled control or Bmi-1 siRNA
were treated with or without cisplatin for 48 h. NAC pre-treatment was done for 1 h before addition of cisplatin where appropriate.
doi:10.1371/journal.pone.0017918.g001
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corroborate our previous observations on apoptosis and posits
ROS as the primary reason for enhanced sensitization of ovarian
cancer cells to cisplatin. In order to determine a cause for the
exacerbated ROS mediated apoptosis observed we next deter-
mined total cellular glutathione (GSH) levels.
Bmi-1 regulates GSH production
Reduced GSH is a critical component of the cell’s antioxidant
network, being directly involved in scavenging ROS and in
maintaining thiol proteins in their reduced state [32,33,34]. Thus
to determine a cause for the increased ROS mediated apoptosis
observed in Bmi-1 silenced cells, we next determined total
intracellular GSH levels. Lysates were prepared from scrambled
control or Bmi-1 siRNA transfected cells treated with or without
cisplatin. Knockdown of Bmi-1 alone significantly decreased
cellular GSH levels (,30% in A-2780 and ,40% in CP-70) and
this was further decreased when combined with cisplatin treatment
(,45% in A-2780 and ,56% in CP-70) (Fig. 3). Cisplatin
treatment alone however had no effect on GSH levels. These data
suggests that at least some of the oxidative stress mediated effects
observed in the Bmi-1 knockdown ovarian cancer cells is due to
decreased intracellular GSH levels.
To further investigate the cause of reduced GSH content in
Bmi-1 silenced cells we next determined whether the expression
levels of the key enzymes involved in the GSH biosynthesis
pathway were altered. We performed quantitative RT-PCR to
determine the gene expression level of glutamate-cysteine ligase
(GCLM) and glutathione synthase (GSS), in the Bmi-1 siRNA
transfected ovarian cancer cell lines. Glutamate-cysteine ligase
(GCLM) is the first rate-limiting enzyme of the glutathione
biosynthesis pathway [35]. In the second step, glutathione synthase
(GSS), converts gamma-L-glutamyl-L-cysteine to glutathione [35].
While mRNA expression of Bmi-1 was reduced as expected in
Bmi-1 silenced cells, interestingly mRNA expression of GCLM
significantly decreased while that of GSS increased (Fig. 3). The
trend was similar in both ovarian cancer cell lines. These results
suggest that perturbation of GCLM, the rate-limiting enzyme is
sufficient to reduce total cellular GSH levels and subsequent fold
increase in GSS mRNA levels probably represent a defense
mechanism for the cells trying to relieve oxidative stress.
Bmi-1 modulates the DDR pathway
To further investigate the mechanism of ROS mediated
enhanced apoptosis by cisplatin in Bmi-1 silenced ovarian cancer
cells we wanted to test the involvement of the DNA damage and
repair (DDR) pathway. Previous studies have reported that
oxidative stress can trigger activation of the DDR pathway [36].
In order to test this we determined phosphorylation levels of Chk2
and H2AX two important biomarkers for DNA damage and
activation of the DDR pathway [37]. Cisplatin treatment alone
induced phosphorylation of Chk2 and H2AX in a concentration
dependent manner and knockdown of Bmi-1 further exacerbated
this effect (Fig. 4A). In corroboration, increased nuclear foci
formation was observed by 53 BP1 immunoflourescence in CP-70
Bmi-1 knockdown cells treated with cisplatin (Fig. 4B). These
results indicate that sustained levels of ROS generated upon Bmi-1
knockdown coupled with cisplatin treatment are sufficient to
directly damage the DNA and engage the DDR pathway. A large
body of literature supports that DNA damage can lead to
apoptosis via activation of caspases [38,39]. Therefore we next
proceeded to determine activation of caspases in Bmi-1 silenced
ovarian cancer cells treated with or without cisplatin.
Bmi-1 regulates effectors of apoptosis
Establishedmediatorsofapoptosisincludecaspases[40].Wenext
determined cleavage of caspase 8 and caspase 9 in control
scrambled or Bmi-1 siRNA transfected cells treated with or without
cisplatin. Cisplatin treatment alone caused cleavage of caspase 8 but
not caspase 9. It is plausible that with higher concentrations of
cisplatin cleavage of caspase 9 could be observed. Importantly
however, combination of Bmi-1 knockdown and cisplatin treatment
significantly and dose dependently increased cleavage of caspase 8
and caspase 9 in both the cell lines (Fig. 5).
PARP is one of the main cleavage targets of activated caspases
and cleaved PARP facilitates cellular disassembly and serves as a
marker of cells undergoing apoptosis [40]. In Bmi-1 knockdown
cells, clear cleavage of PARP was observed in a cisplatin dose
Figure 2. Bmi-1 knockdown increases cisplatin-mediated ROS production in ovarian cancer cells. Ovarian cancer cells transfected with
scrambled control or Bmi-1 siRNA were treated with or without cisplatin for 24 h. Subsequently the cells were incubated with 5 mM carboxy-
H2DCFDA in fresh HBSS for 30 min at 37uC. The cells were harvested with trypsin and fluorescence of the labeled cells was measured at an excitation
wavelength of 485 nm and emission wavelength of 530 nm by using Fluorolog 3 (Jobin-Yvon Horiba). Ratio of mean fluorescence intensity (MFI) with
respect to the untreated scrambled control is represented.
doi:10.1371/journal.pone.0017918.g002
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cisplatin treatment of Bmi-1 knockdown cells enhances apoptosis
by increasing ROS production, causing engagement of the DDR
pathway and activating caspases. We next proceeded to determine
the therapeutic efficacy of silencing Bmi-1 in an orthotopic
chemoresistant mouse model of ovarian cancer.
Knockdown of Bmi-1 enhances cisplatin sensitivity in
vivo
Next the therapeutic potential of Bmi-1 was tested by in vivo
delivery of Bmi-1 siRNA using DOPC (1,2-dioleoyl-sn-glycero-3-
phosphatidylcholine) nanoliposomes in the orthotopic CP-20 mouse
model. This method of delivery has been extensively characterized
previously for duration of knockdown and has been shown to lack
non-specific inflammatory responses [41,42]. To simulate treatment
of advanced small-volume disease, therapy was initiated 1 week after
tumor cellinjection. Mice were divided into the following four groups
(n=10 mice per group): (a) control siRNA-DOPC (150 mg/kg i.p.
twice weekly), (b) control siRNA-DOPC + cisplatin (160 mg/mouse
i.p. weekly), (c) Bmi-1 siRNA-DOPC (150 mg/kg i.p. twice weekly),
and (d) Bmi-1 siRNA-DOPC + cisplatin (doses same as individual
treatments). All of the animals were sacrificed after 4 weeks of
therapy. Efficient knockdown of Bmi-1 (,85%) was first confirmed
by RT-PCR (Fig. 6A). Treatment with Bmi-1 siRNA alone resulted
in significant (,60%) reduction in tumor weight compared to the
control siRNA group. Combination therapy with Bmi-1 siRNA and
c i s p l a t i nr e s u l t e di ne v e ng r e a t e r( ,80%) reduction in tumor weight
compared to the cisplatin only treated group (Fig. 6B). To further
evaluate this effect, the number of tumor nodules formed in each
group was determined. Again combination therapy showed greatest
effect with ,70% fewer tumor nodules compared tothe cisplatinonly
treated group (Fig. 6B). No obvious toxicity was noted in the animals
during therapy experiments as assessed by changes in behavior,
feeding habits, and mobility. The mean body weight was also similar
between the treatment groups (data not shown).
Effect of Bmi-1 knockdown on proliferation and
apoptosis in vivo
To corroborate our in vitro data we next examined the effect of
Bmi-1 knockdown on in vivo tumor cell proliferation and apoptosis
Figure 3. Bmi-1 knockdown perturbs the GSH biosynthesis pathway. The top panel represents total cellular GSH measured (Materials and
methods) in ovarian cancer cells transfected with scrambled control or Bmi-1 siRNA treated with or without cisplatin for 24 h. The bottom panel
represents fold change in gene expression (normalized with beta actin and compared to scrambled control) as determined by quantitative RT-PCR of
ovarian cancer cells transfected with scrambled control or Bmi-1 siRNA for 48 h.
doi:10.1371/journal.pone.0017918.g003
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Bmi-1 siRNA and cisplatin showed the greatest effect with ,50%
decrease in proliferation compared to the control untreated group
(Fig. 7). Similarly, an approximately 80% increase in apoptosis was
observed in the combination therapy group compared to the
control treated group (Fig. 7). Therefore we demonstrate that
silencing of Bmi-1 in ovarian cancer cells whether in vitro or in vivo
increases apoptosis in response to cisplatin.
Discussion
Undoubtedly ovarian cancer is a vexing, incurable disease for
patients with recurrent cancer and therapeutic options are limited
[1,43]. Here we demonstrate Bmi-1 gene silencing as an effective
option, which in combination with cisplatin enhances therapeutic
efficacy even further. Moreover we delineate the mechanism of
increased sensitivity to be primarily through ROS production.
Figure 4. Bmi-1 knockdown augments engagement of the DDR pathway in cisplatin treated ovarian cancer cells. (A) Ovarian cancer
cells transfected with scrambled control or Bmi-1 siRNA were treated with or without cisplatin for 48 h. Western blot was performed for phospho
Chk-2, total Chk-2, phospho-H2AX, total H2AX and beta actin using respective antibodies. (B) Scrambled control or Bmi-1 siRNA transfected CP-70
cells were subjected to confocal microscopy using 53BP1 antibody (red) and DAPI (blue nuclear staining) to demonstrate nuclear foci formation.
doi:10.1371/journal.pone.0017918.g004
Figure 5. Effect of Bmi-1 knockdown on apoptotic markers. Ovarian cancer cells transfected with scrambled control or Bmi-1 siRNA were
treated with or without cisplatin for 48 h. Western blot was performed for caspase-8, caspase-9 and PARP using respective antibodies.
doi:10.1371/journal.pone.0017918.g005
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platinum/taxane regimen, which are known to induce ROS
production. We posit that knockdown of Bmi-1 will prove
efficacious in combination therapy with this regimen. In this
context a recent report has demonstrated Bmi-1 to be recruited
early to the double-strand break site upon ionizing radiation
damage [44]. Our results corroborate and extend this idea and
demonstrate in vitro and in vivo that Bmi-1 silencing synergizes with
increased oxidative stress leading to accumulation of DNA damage
and apoptosis.
At least two previous publications demonstrated increased ROS
levels in neurons, thymocytes and bone marrow cells isolated from
Bmi-1 null mice [28,29]. However the cause for this ROS
production has been varyingly ascribed to p53 dependent and
independent repression of anti-oxidant gene expression or
impaired mitochondrial energetics [28,29]. We show here that
in addition to these pathways Bmi-1 also controls cellular GSH
levels by regulating transcription of the enzymes involved in the
GSH biosynthesis pathway. Notably transcription of GCLM is
positively regulated by transcription factors such as Nrf-1 and
NFkB. In the context of Bmi-1 knockdown, both of these
transcription factors are downregulated in neurons and glioma
cells respectively [28,45]. Therefore it is possible that Bmi-1
silencing leads to downregulation of Nrf-1 and or NFkB in ovarian
cancer cells, thereby decreasing transcription of GCLM resulting
in reduced GSH synthesis. Importantly here we show that Bmi-1
by regulating ROS and GSH levels protects the ovarian cancer
cells from chemotherapeutic insults.
The DNA damage response pathway can be activated by
genotoxic stress such as those caused by chemotherapeutics and
oxidative DNA damage. Indeed activation of DDR can lead to a
pause in cell cycle progression, senescence or apoptosis. In
accordance we find that the dual insult of oxidative damage
caused by Bmi-1 knockdown and cisplatin treatment, which is
known to cause double strand breaks in the DNA along with ROS
production tips the threshold for ovarian cancer cells towards
apoptosis by inducing phosphorylation of i) Chk2 and H2AX, ii)
causing nuclear foci formation by 53BP1 and cleavage of apoptotic
markers such as iii) caspases and PARP.
As we have demonstrated in our in vivo experiments, knockdown
of Bmi-1 could be useful in clinical settings due to the following
reasons; a) downregulation of Bmi-1 enhances cisplatin-induced
apoptosis in ovarian cancer cells. b) Bmi-1 is required for self-
renewal and maintenance of stem cells including ovarian cancer
stem cells which by definition are resistant to chemotherapeutics
[23]. c) Bmi-1 regulates multiple pathways, most prominent of
which is induction of telomerase leading to immortalization of
mammary epithelial cells [46]. d) Downregulation of Bmi-1 leads
to de-repression of ink4a, which encodes tumor suppressors
p16Ink and p19Arf that regulate senescence and apoptosis [47].
Activation of these pathways have been invoked as an important
tumor suppressor barrier, because these pathways act as potent
inhibitors of proliferation or propagation of damaged cells. e) In
addition we posit that cisplatin and Bmi-1 act on similar pathways
affecting mitochondrial function and/or through increased ROS
generation cause DNA damage leading to efficient induction of
Figure 6. Effect of Bmi-1 knockdown on orthotopic chemoresistant ovarian cancer growth. To assess the effects of siRNA therapy on
tumor growth, treatment was initiated 1 wk after i.p. injection (1.0610
6 CP20) of tumor cells. Mice were divided into four groups (n=10 mice per
group): (a) control siRNA-DOPC (150 mg/kg i.p. twice weekly), (b) control siRNA-DOPC + cisplatin (160 mg/mouse i.p. weekly), (c) Bmi-1 siRNA-DOPC
(150 mg/kg i.p. twice weekly), and (d) Bmi-1 siRNA-DOPC + cisplatin (doses same as individual treatments). Treatment was continued until 4 weeks
after tumor inoculation before sacrifice. (A) Total RNA was isolated from a portion of the tumor tissues and subjected to RT-PCR using primers for
Bmi-1 and beta actin. The comparative Ct method was used to calculate the relative abundance of mRNA compared with that of beta actin
expression. The experiment was performed in triplicate and significance determined using two-sided Student’s t test, P,0.05 was considered
significant. (B) Mouse and tumor weights and (C) the number of tumor nodules for each group were compared using Student’s t test (for
comparisons of two groups). A two-tailed P#0.05 was deemed statistically significant.
doi:10.1371/journal.pone.0017918.g006
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signal initiating apoptosis. Thus, Bmi-1 is an important new target
for therapy not only in chemoresistant ovarian cancer but also for
other malignancies characterized by overexpression of Bmi-1.
Materials and Methods
Reagents
Bmi-1 antibody was from Zymed, CA, USA. Bmi-1 and scrambled
control siRNA were from Sigma-Aldrich Sigma-Aldrich, St. Louis,
MO. Phospho-H2AX, Phospho-Chk-2, 53 BP1 cleaved caspase-8,
caspase-9 and PARP antibodies were from Cell Signaling Technologies
Inc., MA. Annexin/FITC-PI apoptosis kit was from Biovision Inc.
Cell Culture
A-2780 and CP-70 cells were grown in RPMI with 10% FBS
and 1% antibiotic (Penicillin/Streptomycin) according to the
provider’s recommendation. The CP-20 cell lines were grown
according to our previously published procedures [48].
SiRNA transfection
The ovarian cells A2780 or CP-70 were grown in their
respective medium for one day prior to transfection. Using
oligofectamine the cells were transfected with 25 nM scrambled
control or Bmi-1 siRNA. After 48 h the cells were processed for
western blot or apoptosis assays [49].
Western Blot
Harvested ovarian cancer cells, both treated and non-treated,
were washed in PBS and lysed in ice-cold radioimmunoprecipi-
tation (RIPA) buffer with freshly added 0.01% protease inhibitor
cocktail (Sigma) and incubated on ice for 30 min. Cell debris was
discarded by centrifugation at 13000 rpm for 10 min at 4uC and
the supernatant (30–50 mg of protein) was run on an SDS-Page
[49].
ROS assay
The ovarian cancer cell lines transfected with the scrambled
control or Bmi-1 siRNA were treated with cisplatin for 24 hrs.
After washing with HBSS, the cells were incubated with 5 mM
carboxy-H2DCFDA (Invitrogen, Carlsbad, CA) [50] in fresh
HBSS for 30 min at 37uC. Excessive probe was washed off. The
cells were harvested with trypsin and fluorescence of the labeled
cells was measured at an excitation wavelength of 485 nm and
emission wavelength of 530 nm by using Fluorolog 3 (Jobin-Yvon
Horiba). The experiment was repeated three times and mean
fluorescence intensity (MFI) [50] was recorded. Statistical
significance was determined using two-sided Student’s t test, and
P,0.05 was considered significant.
Apoptosis assay
Ovarian cancer cells transfected with scrambled control or Bmi-
1 siRNA for 48 h were treated with cisplatin for another 48 h. For
experiments using NAC, it was applied 1 h before addition of
cisplatin. Cells were subjected to Annexin-FITC/PI staining and
flourescence recorded using a FACSCalibur flow cytometer
(Becton-Dickinson). The experiment was performed in triplicate
and significance determined using two-sided Student’s t test,
P,0.05 was considered significant.
Figure 7. Knockdown of Bmi-1 leads to decreased proliferation and increased apoptosis of ovarian tumor in vivo. (A)
Immunohistochemical staining for Ki67 and (B) TUNEL was conducted to assess cell proliferation and apoptosis. Original magnification 200X.
Quantification is shown graphically on the right. Treatment arms were compared using Student’s t test and P#0.05 was deemed statistically
significant.
doi:10.1371/journal.pone.0017918.g007
Bmi-1, a Therapeutic Target in Ovarian Cancer
PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e17918GSH assay
The assay was performed according to manufacturer’s protocol
(Cayman Chemicals). Briefly, the ovarian cancer cell lines
transfected with the scrambled control or Bmi-1 siRNA were
treated with cisplatin for 24 hrs. The cell were lysed by sonication
and collected in 50 mM phosphate buffer by centrifugation at
10,000 g for 15 min at 4uC. The lysates were next de-proteinated
using the TEAM reagent and total cellular GSH determined
against a standard curve generated at the same time by measuring
absorbance at 405 nm 25 min after addition of assay cocktail. The
experiment was performed in triplicate and significance deter-
mined using two-sided Student’s t test, P,0.05 was considered
significant.
Realtime PCR
Total RNA was isolated from transfected cells using TRIzol
reagent (Invitrogen). RNA was first retrotranscribed using
TaqManH Reverse Transcription Kit (Applied Biosystems) and
then realtime PCR was carried out using and TaqManH SYBR
Green Master Mix (Applied Biosystems). The primers for human
Bmi-1, GCLM, GSS and beta actin were from SA Bioscienes,
Frederick, MD. The comparative Ct method was used to calculate
the relative abundance of mRNA compared with that of beta actin
expression [51]. The experiment was performed in triplicate and
significance determined using two-sided Student’s t test, P,0.05
was considered significant.
Liposomal siRNA preparation
For in vivo delivery, siRNA was incorporated into DOPC as
previously described [48]. Briefly, siRNA and DOPC were mixed
at a ratio of 1:10 (w/w) siRNA/DOPC in excess tertiary butanol.
Tween 20 was added to the mixture at the ratio of 1:19 (Tween
20:siRNA/DOPC). After vortexing, the mixture was frozen in an
acetone/dry ice bath and lyophilized. Before in vivo administra-
tion, this mixture was hydrated with 0.9% saline to a
concentration of 25 mg/mL and 200 mL of mixture were used
per injection.
Orthotopic model of ovarian cancer
Female athymic nude mice (NCr-nu) were purchased from
the National Cancer Institute-Frederick Cancer Research and
Development Center (Frederick, MD). All mice were housed
and maintained under specific pathogen-free conditions in
facilities approved by the American Association for Accredi-
tation of Laboratory Animal Care (Acuf# 12-02-18233) and in
accordance with current regulations and standards of the U.S.
Department of Agriculture, U.S. Department of Health and
Human Services, and NIH. All studies were approved and
supervised by the University of Texas M. D. Anderson Cancer
Center Institutional Animal Care and Use Committee. All
mice were used in these experiments when they were 8 to
12 wk old.
Before injection, tumor cells were washed twice with PBS,
detached by 0.1% cold EDTA, centrifuged for 7 min, and
reconstituted in HBSS (Invitrogen). Cell viability was confirmed
by trypan blue exclusion. Tumors were established by i.p.
injection of either 1.0610
6 CP20 cells. Once established, this
tumor model reflects the growth pattern of advanced ovarian
cancer [42].
To assess the effects of siRNA therapy on tumor growth,
treatment was initiated 1 wk after i.p. injection of tumor cells.
Mice were divided into four groups (n=10 mice per group): (a)
control siRNA-DOPC (150 mg/kg i.p. twice weekly), (b) control
siRNA-DOPC + cisplatin (160 mg/mouse i.p. weekly), (c) Bmi-1
siRNA-DOPC (150 mg/kg i.p. twice weekly), and (d) Bmi-1
siRNA-DOPC + cisplatin (doses same as individual treatments).
Treatment was continued until 4 weeks after tumor inoculation. At
the time of sacrifice, mouse weight, tumor weight, number of
nodules, and distribution of tumors were recorded. Tissue samples
were snap frozen for lysate preparation or fixed in formalin for
paraffin embedding. The individuals who did the necropsies,
tumor collections, and tissue processing were blinded to the
treatment group assignments.
Immunohistochemistry
Ki67 and terminal deoxynucleotidyl transferase–mediated
dUTP nick end labeling (TUNEL) staining were done using
formalin-fixed, paraffin-embedded tumor sections (8 mm thickness)
as previously described [48]. Briefly, after deparaffinization and
rehydration, antigen retrieval was done using citrate buffer
(0.1 mol/L; pH 6.0) in a microwave. Endogenous peroxidase
and nonspecific epitopes were blocked with 3% H2O2/methanol
for 12 min and 5% normal horse serum and 1% normal goat
serum for 20 min. Sections were incubated with primary anti-
Ki67 overnight at 4uC and secondary horseradish peroxidase–
conjugated antibody (Serotec Bioproducts) for 1 h at room
temperature. Horseradish peroxidase was detected with 3,39-
diaminobenzidine (Phoenix Biotechnologies) substrate for 5 min,
washed, and counterstained with Gill’s no.3 hematoxylin (Sigma-
Aldrich) for 15 s and mounted.
To quantify apoptosis, we did TUNEL staining on 8-mm-thick
paraffin-embedded tumor slides as previously described [48].
Briefly, after deparaffinization, slides were treated with proteinase
K (1:500) and a positive control slide was treated with DNase.
Endogenous peroxidase activity was blocked with 3% H2O2 in
methanol. After being rinsed with TdT buffer (30 mmol/L
Trizma, 140 mmol/L sodium cacodylate, 1 mmol/L cobalt
chloride), slides were incubated with terminal transferase
(1:400; Roche Diagnostics) and biotin-16-dUTP (1:200; Roche
Diagnostics) and blocked with 2% bovine serum albumin. Slides
were then incubated with peroxidase streptavidin (1:400) at 37uC
for 40 min, visualized with 3,39-diaminobenzidine chromogen,
and counterstained with Gill’s hematoxylin. The apoptotic and
proliferative indices were determined by the number of positive
cells in five randomly selected high-power fields exclusive of
necrotic areas. To quantify Ki67 expression and apoptotic cells,
the number of positive cells (3,39-diaminobenzidine staining) was
counted in 10 random 0.159 mm2 fields at 6100 magnification.
All staining was quantified by two investigators in a blinded
fashion.
Statistical analysis
All values are expressed as means6SD. Statistical significance
was determined using two-sided Student’s t test, and a value of
P,0.05 (*) was considered significant.
For animal experiments, 10 mice were assigned per treatment
group. To judge the necessary sample size for proposed
experiments, we considered a two-way ANOVA model. For an
effect size (ratio of fixed effect and residual SD) of 1.3, this sample
size will be sufficient to provide 80% power for a test at
significance level of 0.05. Mouse and tumor weights and the
number of tumor nodules for each group were compared using
Student’s t test (for comparisons of two groups). Statistical analyses
were done using Statistical Package for the Social Sciences 12.0 for
Windows (SPSS, Inc.). A two-tailed P#0.05 was deemed
statistically significant.
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